What is Vandetanib?

Vandetanib (Vandetanib) is a once-daily oral formulation with potential for use in multiple solid tumor types. Vandetanib targets key signaling pathways in cancer by inhibiting VEGFR-dependent tumor angiogenesis, EGFR- and RET-dependent tumor cell proliferation and survival. Phase I studies have shown that vandetanib is generally well tolerated at doses less than or equal to 300 mg/day, and its pharmacokinetic profile supports once-daily oral administration.

In April 2011, the U.S. Food and Drug Administration (FDA) approved vandetanib for the treatment of adults with unresectable, locally advanced, or metastatic medullary thyroid carcinoma (MTC) as an alternative to local treatment of unresectable and disseminated disease. Because vandetanib prolongs the Q-T interval, it is contraindicated in patients with serious cardiac complications (such as congenital long QT syndrome and decompensated heart failure) and should be closely monitored for adverse events including QT prolongation, as these events may not completely resolve until approximately three plasma half-lives of the drug. A phase II evaluation of vandetanib in patients with advanced refractory non-small cell lung cancer demonstrated improved progression-free survival either as monotherapy (versus gefitinib) or in combination with docetaxel (versus docetaxel alone).

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.